Latest news

Fatigue and blurred vision were the first signs for Chloe Baker that something wasn’t right. In 2017, the 31-year-old moved home from New Zealand to be with her family and focus on her health. An eye test led to an MRI, and then a diagnosis of multiple sclerosis (MS).

The Pharmaceutical Benefits Advisory Committee (PBAC) have announced they have not recommended the listing of MAVENCLAD® (cladribine tablets) for relapsing remitting MS (RRMS) on the Pharmaceutical Benefits Scheme (PBS).

For two years Kent Piercy developed an increasing stiffness and slowness in both arms and a reduced swing in his right arm. Naturally concerned about these changes, Kent saw a neurologist early last year, and at the age of 74 was diagnosed with tremor-dominant idiopathic Parkinson’s.

Fatigue and blurred vision were the first signs for Chloe Baker that something wasn’t right. The 31-year-old moved home from New Zealand to be with her family and focus on her health. An eye test led to an MRI, and then a diagnosis of multiple sclerosis.

How the brain works has intrigued Associate Professor Jenny Rodger for almost 30 years, with a lot of her work focusing on brain plasticity – the ability of the brain to change throughout someone’s life by rewiring or modifying neural connections.

Pharmaceutical companies Biogen and AbbVie has announced the voluntary worldwide withdrawal for ZINBRYTA ® (daclizumab) for Relapsing multiple sclerosis.

Ocrevus ™ is used in relapsing remitting multiple sclerosis (RRMS) and this morning, the Federal Government announced the listing of the drug on the PBS.

Legendary Australian track and field Olympian Betty Cuthbert, AM, MBE has been posthumously honoured with a Companion AC in the General Division of the Order of Australia for eminent service to athletics at the national and international level, particularly as a gold medallist at the Melbourne and Tokyo Olympic Games, and as a role model, fundraiser, and advocate for research into finding a cure for multiple sclerosis (MS).

In a world-first, a Perth Professor has delayed the development of MS in high-risk individuals using narrowband UVB treatment, something used to treat the skin condition psoriasis. Trials conducted by Professor Prue Hart found that in 3 out of 10 people, with a single episode of MS who were treated with UVB, the progression of their MS was halted.

It was announced today that Western Australia will join the federally-funded National Disability Insurance Scheme (NDIS), replacing the WA-based scheme set up b the former Government.